

Table SIII. Analysis of drug survival at selected time-points

	Anti-TNF- α agent	Time-point, month	Treatment cycles, <i>n</i>	Events, ^a	Drug survival, %	Standard error	Lower 95% CI	Upper 95% CI	
Intention-to-treat analysis	Adalimumab	0	460	0	1.000	0.0000	1.000	1.000	
		4	387	33	0.925	0.0126	0.896	0.946	
		12	245	84	0.709	0.0229	0.661	0.751	
		24	150	42	0.570	0.0267	0.516	0.620	
		36	75	11	0.516	0.0289	0.458	0.571	
		48	23	2	0.496	0.0310	0.434	0.555	
	Etanercept	0	501	0	1.000	0.0000	1.000	1.000	
		4	432	50	0.898	0.0136	0.868	0.922	
		12	316	89	0.708	0.0209	0.664	0.746	
		24	241	42	0.608	0.0230	0.561	0.651	
		36	184	18	0.560	0.0238	0.512	0.605	
		48	134	20	0.492	0.0253	0.441	0.540	
		60	92	11	0.446	0.0265	0.394	0.497	
		72	55	11	0.382	0.0291	0.325	0.438	
	Infliximab	0	58	0	1.000	0.0000	1.0000	1.000	
		4	51	7	0.879	0.0428	0.7634	0.941	
		12	32	17	0.580	0.0655	0.4419	0.696	
		24	16	15	0.301	0.0622	0.1860	0.424	
		36	11	4	0.226	0.0569	0.1257	0.344	
		48	5	5	0.117	0.0461	0.0464	0.224	
		60	3	0	0.117	0.0461	0.0464	0.224	
		72	2	0	0.117	0.0461	0.0464	0.224	
	Per-protocol analysis	Adalimumab	0	460	0	1.000	0.0000	1.000	1.000
			4	382	33	0.924	0.0127	0.895	0.946
12			237	79	0.716	0.0230	0.668	0.758	
24			140	38	0.581	0.0273	0.526	0.633	
36			69	10	0.528	0.0298	0.468	0.584	
48			18	2	0.506	0.0324	0.441	0.567	
Etanercept		0	501	0	1.000	0.0000	1.000	1.000	
		4	428	49	0.900	0.0136	0.870	0.923	
		12	304	84	0.715	0.0210	0.672	0.754	
		24	225	37	0.622	0.0232	0.574	0.665	
		36	166	15	0.577	0.0243	0.528	0.623	
		48	122	14	0.522	0.0261	0.469	0.571	
		60	82	10	0.474	0.0278	0.418	0.527	
		72	48	9	0.410	0.0314	0.348	0.470	
Infliximab		0	58	0	1.000	0.0000	1.0000	1.000	
		4	50	7	0.879	0.0430	0.7622	0.940	
		12	29	16	0.581	0.0673	0.4386	0.700	
		24	13	14	0.282	0.0647	0.1640	0.411	
		36	9	3	0.213	0.0599	0.1095	0.338	
		48	4	4	0.113	0.0488	0.0405	0.228	
		60	2	0	0.113	0.0488	0.0405	0.228	
		72	2	0	0.113	0.0488	0.0405	0.228	
Worst-case scenario analysis, as described in Materials and Methods		Adalimumab	0	460	0	1.000	0.0000	1.000	1.000
			4	382	39	0.911	0.0137	0.880	0.934
	12		237	91	0.678	0.0235	0.630	0.722	
	24		140	47	0.524	0.0270	0.470	0.575	
	36		69	13	0.460	0.0291	0.403	0.516	
	48		18	4	0.424	0.0322	0.360	0.486	
	Etanercept	0	501	0	1.000	0.0000	1.000	1.000	
		4	428	54	0.890	0.0141	0.859	0.915	
		12	304	98	0.681	0.0215	0.637	0.721	
		24	225	49	0.565	0.0233	0.518	0.609	
		36	166	20	0.511	0.0240	0.463	0.557	
		48	122	16	0.457	0.0251	0.407	0.505	
		60	82	11	0.411	0.0261	0.359	0.461	
		72	48	9	0.355	0.0286	0.300	0.411	
	Infliximab	0	58	0	1.0000	0.0000	1.0000	1.000	
		4	50	8	0.8621	0.0453	0.7431	0.929	
		12	29	20	0.5147	0.0659	0.3794	0.634	
		24	13	16	0.2307	0.0560	0.1316	0.346	
		36	9	4	0.1597	0.0487	0.0788	0.266	
		48	4	4	0.0852	0.0380	0.0299	0.178	
		60	2	0	0.0852	0.0380	0.0299	0.178	
		72	2	0	0.0852	0.0380	0.0299	0.178	
	84	1	0	0.0852	0.0380	0.0299	0.178		

CI: confidence interval; TNF- α : tumour necrosis factor- α .

Note: there were no overlaps in the confidence intervals comparing infliximab with adalimumab and etanercept at 24 months and thereafter.